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Vitamin D is a multifunctional hormone that can affect many
essential biological functions, ranging from the immune
regulation to mineral ion metabolism. A close association
between altered activity of vitamin D and vascular
calcification has been reported in various human diseases,
including in patients with atherosclerosis, osteoporosis, and
chronic kidney disease (CKD). Vascular calcification is a
progressive disorder and is a major determinant of morbidity
and mortality of the affected patients. Experimental studies
have shown that excessive vitamin D activities can induce
vascular calcification, and such vascular pathology can be
reversed by reducing vitamin D activities. The human
relevance of these experimental studies is not clear, as
vitamin D toxicity is relatively rare in the general population.
Contrary to the relationship between vitamin D and vascular
calcification, in experimental uremic models, low levels of
vitamin D were shown to be associated with extensive
vascular calcification, a phenomenon that is very similar to
the vascular pathology seen in patients with CKD. The
current treatment approach of providing vitamin D analogs
to patients with CKD often poses a dilemma, as studies linked
vitamin D treatment to subsequent vascular calcification.
Recent genetic studies, however, have shown that vascular
calcification can be prevented by reducing serum phosphate
levels, even in the presence of extremely high serum
1,25-dihydroxyvitamin D and calcium levels. This article will
briefly summarize the dual effects of vitamin D in vascular
calcification and will provide evidence of vitamin
D-dependent and -independent vascular calcification.
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VITAMIN D
Vitamin D is a multifunctional hormone that exerts
effects on most of the organ systems.1–7 Calcitriol or 1,25-
dihydroxyvitamin D is the active form of vitamin D, formed
by dual hydroxylation in the liver and kidney (Figure 1).
Active vitamin D metabolites exert biological activities
mainly through the vitamin D receptor (VDR).8 There are
numerous factors that can influence vitamin D production.
For instance, parathyroid hormone induces the synthesis of
1-a hydroxylase in proximal tubular epithelial cells to
produce 1,25-dihydroxyvitamin D. Similarly, low serum
levels of phosphate can also induce the biosynthesis of
1,25-dihydroxyvitamin D in the proximal tubular epithelial
cells. Circulating 1,25-dihydroxyvitamin D, acting through
VDR, can enhance the intestinal absorption of calcium and
phosphate, while can also suppress the biosynthesis of
parathyroid hormone.9 In bones, high levels of 1,25-
dihydroxyvitamin D usually increases osteoclastic bone
resorption to mobilize calcium and phosphate into the
circulation to ensure optimal serum balance.
In contrast to the endocrine effects of VDR, the autocrine
functions of VDR require local generation of the active ligand
(calcitriol). VDRs are present in most of the human tissues,
including endothelial and vascular smooth muscle cells
(VSMCs).10,11 More importantly, VSMCs also possess an
enzymatically active 25-hydroxyvitamin D-1a-hydroxylase
system12 and can synthesize active vitamin D metabolites
locally. Therefore, the circulating levels of calcitriol may not
always reflect vascular activities of vitamin D. Moreover, 1a-
hydroxylase activity was also detected in endothelial cells.13
Experimental studies have shown that calcitriol can increase
the expression of the VDR and decrease the proliferation
of VSMCs.11,14 Furthermore, calcitriol can accelerate cell
migration and promote the transition of contractile VSCMs
into the osteoblast-like phenotype.15,16 It appears likely that
autocrine, paracrine, and endocrine functions of vitamin D
can influence vascular structure, functions, and remodeling.
Importantly, the above mentioned effects of vitamin D on
blood vessels are in addition to the most commonly
appreciated functions of vitamin D in active regulation of
mineral ion metabolism, such as facilitating intestinal
calcium absorption, as well as renal, and skeletal mobilization
of phosphate.8,17,18 More importantly, vitamin D is a strong
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inducer of fibroblast growth factor 23 (FGF23) and klotho,
two important factors that maintain physiologic calcium and
phosphate balance.19,20 Of particular interest, loss-of-func-
tion mutations of either FGF23 or klotho can induce ectopic
calcification in the affected patients.21–23 Because survival can
be negatively influenced by vascular calcification, minimizing
the risk of such vascular pathology requires that the
molecular mechanisms involved in the tightly controlled
regulatory pathways and cross talk between organ systems be
understood.
VASCULAR CALCIFICATION
Vascular calcification is a complex process that induces
stiffening of the vessel wall and reduces vascular compli-
ance.24 The exact molecular mechanisms of vascular
calcification is not yet clear; it seems that an initial insult
to the cellular components of the vessels can function as a
triggering event, which is further facilitated by the presence of
calcifying-promoting factors such as hypervitaminosis D,
hyperphosphatemia, and hypercalcemia.25–28 Studies also
suggested that reduction of the calcification repressor factors,
such as ectonucleotide pyrophosphatase/phosphodiesterase 1
(NPP-1), ANK (transmembrane protein), and matrix Gla
protein, can also propagate vascular calcification.29–31 For
instance, matrix Gla protein deficiency in humans (Keutel
syndrome) and in genetically modified mice (matrix Gla
protein knockout) is associated with ectopic calcification.32,33
Matrix Gla protein is thought to suppress vascular calcifica-
tion partly through its Gla residues, which have a calcium/
hydroxyapatite-chelating ability. In a similar study, in vivo
ablation of the ANK gene from mice resulted in ectopic
calcification.34 Interestingly, blocking the pyrophosphate
degrading action of alkaline phosphatase can reduce the
calcification in VSMCs obtained from genetically altered
NPP-1- and ANK-deficient mice.35 Vascular calcification was
also detected in patients with loss-of-function mutations in
the human NPP-1 gene.36 Studies have shown that in the
absence of calcification repressor factors, calcification can
occur at normal calcium and phosphate levels.
Vascular calcification was previously considered as a
passive process related to non-specific responses and had
little clinical significance. However, availability of electron
beam and multidetector row computed tomography imaging
helped clinicians to monitor the in vivo active progression of
vascular calcification and predict consequences of acute and
chronic coronary events. Furthermore, recent identification
of calcification-promoting and -suppressing factors (Table 1)
provided convincing molecular evidence that vascular
calcification is not only an active process, but one that may
be reversible if manipulated in early stages. For instance,
hyperphosphatemia in dialysis patients correlates with
vascular calcification, and reducing phosphate levels can
attenuate progression of vascular calcification in these
patients.37 Prevention of vascular calcification is of great
clinical importance, as it can induce fatal complications such
as thrombosis, arterial rupture, and myocardial infarction.
Vascular calcification often mimics certain molecular
events including those seen in skeletal mineralization.38
Alteration of mineral ion balance can induce both endothelial
and VSMC apoptosis, and facilitate phenotypic transforma-
tion of VSMCs into skeletal cells. Studies have linked bone
morphogenetic proteins, RUNX2, MSX2, and activation of
wingless-type MMTV integration site family member signal-
ing to such cellular transformation processes.27,39 Of
relevance, MSX2 can not only promote osteogenesis but
can also suppress adipogenic differentiation of multipotent
mesenchymal progenitors.40 Some researchers believe that
once vascular cells are transdifferentiated into skeletal cells,
subsequent mineralization processes lead to the development
of vascular calcification. As mentioned, vitamin D can induce
transdifferentiation of VSCMs into the osteoblast-like
phenotype promoting the complex process of vascular
calcification.15,16,41
VITAMIN D-DEPENDENT VASCULAR CALCIFICATION
Studies have linked vitamin D therapy to higher incidences of
vascular calcification; in a retrospective study, the severity
and progression of vascular calcification correlated with the
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Figure 1 | Simplified diagram of the different stages of
vitamin D synthesis. VDR, vitamin D receptor.
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plasma levels of vitamin D in chronic kidney disease (CKD)
patients undergoing prolonged dialysis treatment.42 A similar
observation was also reported in young adults suffering from
CKD since childhood; the use of active vitamin D prepara-
tions has shown to be independently associated with
cardiovascular anomalies, including intima–media thickness
and coronary artery calcification.43 In accordance with the
human observations, high doses of vitamin D metabolites
were shown to be associated with the experimental vascular
calcification in rats and other animals.44,45 Exogenous
treatment of vitamin D and nicotine can markedly increase
the aortic calcium content, causing medial elastic fiber
calcification and arterial stiffness in experimental animals.46
A time-dependent aortic calcification was also shown in
calcitriol-treated rats with relatively normal renal function.44
In a separate study, diffuse calcification involving the
intimal and medial layers of the aorta was noted in uremic
rats that received relatively low doses of oral calcitriol
(0.25 mg/kg per day).47 More importantly, calcitriol-induced
vascular calcification has been shown to be a reversible
process, by reducing vitamin D activities.44 Although the
in vivo optimal levels are difficult to estimate, it seems that a
delicate balance of vitamin D is important for normal
vascular functions, as studies have shown that both low and
high vitamin D levels are associated with vascular calcifica-
tion (a U-curve relationship) in pediatric patients under-
going dialysis treatment.48
Vitamin D is a strong inducer of both FGF23 and klotho.
1,25-Dihydroxyvitamin D has been shown to increase FGF23
promoter activity in osteoblasts through a vitamin
D-responsive element.49 In contrast, FGF23 can suppress
1,25-dihydroxyvitamin D activity by reducing renal expres-
sion of 1a-hydroxylase, and increasing 24-hydroxylase.19
Recent studies have elegantly demonstrated the importance
of the FGF23–klotho system in the regulation of calcium and
phosphate balance.50,51
Vitamin D-associated vascular calcification was also noted
in various genetically modified mouse models.51–55 For
instance, genetic inactivation of either Fgf23 or klotho leads
to increased serum calcium, phosphate and 1,25-dihydrox-
yvitamin D levels in these mutant mice; such abnormal
mineral ion and vitamin D homeostasis in Fgf23- and klotho-
knockout mice are associated with widespread soft tissue and
vascular calcifications.53,55 More importantly, genetically
reducing active vitamin D synthesis in either Fgf23- or
klotho-knockout mice can completely eliminate soft tissue and
vascular calcifications in Fgf23/1a(OH)ase and klotho/
1a(OH)ase-double-knockout mice.20,28,51,52,54,56 However, it
should be mentioned that the loss of vitamin D-related
processes, either from Fgf23 or klotho mice resulted in a
change from severe hyperphosphatemia to hypophosphate-
mia. Whether biomineralization of the vascular wall through
excessive deposition of hydroxyapatite can occur without
vitamin D-dependent processes is not yet clear, as dissociating
the in vivo effects of vitamin D from mineral ion dysregula-
tion is difficult to estimate. For instance, experimental
calcification induced by extremely low doses of vitamin D
(0.04mg/kg of calcitriol intraperitoneally three times/week for
1 month) resulted in a marked increase in serum calcium,
phosphate, and the calcium–phosphate (Ca P) product.57
Thus, it is difficult to determine in vivo whether calcitriol can
directly induce vascular calcification or if such vascular
pathology is related to the altered mineral ion balance and
increased Ca P product levels, as seen in these low vitamin
D-treated animals.57 Moreover, neither calcitriol nor its
analogs (paricalcitol or doxercalciferol) (1–100 nM) were able
to induce mineralization in human VSMCs, whereas increas-
ing extracellular phosphate concentration induced minerali-
zation in human VSMCs.58 Consistent with the in vitro
studies, recent in vivo mouse genetic studies have provided
insights into vitamin D-independent vascular calcification.
VITAMIN D-INDEPENDENT VASCULAR CALCIFICATION
Studies have shown a negative correlation between
serum 25-hydroxyvitamin D levels and vascular calcifica-
tions,59 and that both serum 25-hydroxyvitamin D and
Table 1 | Partial list of known inducers and inhibitors of
vascular calcification
Inducers
BMP-2/4
Calcium
Hyperparathyroidism
Inflammatory cytokines
LDL
Leptin
MSX2
Oncostatin
Osteocalcin
Phosphate
Pit-1
RUNX2
TGF-b1
TNAP
Uremic toxins
Vitamin D
Inhibitors
Adiponectin
ANK
BMP-7
Fetuin-A
HDL
IGF-1
Insulin
Klotho
Magnesium
Matrix Gla protein
NPP-1
Omega-3 fatty acid
Osteopontin
Osteoprotogerin
PTH
PTHrP
Pyrophosphate
Abbreviations: ANK, transmembrane protein; BMP, bone morphogenetic protein;
LDL, low-density lipoprotein; IGF-1, insulin-like growth factor-1; NPP-1, pyropho-
sphatase/phosphodiesterase; PTH, parathyroid hormone; PTHrP, PTH-related pep-
tide; TGF-b1, transforming growth factor-b1; TNAP, tissue-non-specific alkaline
phosphatase.
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1,25-dihydroxyvitamin D levels were also negatively corre-
lated with aortic pulse wave velocity.60 The endothelial
functions (determined by flow-mediated vasodilatation) of
type 2 diabetic patients with low levels of vitamin D were
shown to improve with vitamin D treatment.61 Similarly,
vitamin D deficiency has shown to increase the hazard ratio
of incident cardiovascular diseases.62 Shoji et al.63 have
shown lower risk for cardiovascular mortality in CKD
patients using oral 1a-hydroxy vitamin D3 (alfacalcidol) in
a hemodialysis population compared to non-users. In a
similar study, Shoben et al.64 found improved survival in
non-dialyzed CKD patients receiving oral calcitriol therapy.
Collectively, the above mentioned studies clearly suggest that
cardiovascular functions are impaired in vitamin D-deficient
states. Reduced serum levels of 1,25-dihydroxyvitamin D is
one of the major biochemical changes detected in patients with
CKD. The current treatment approach of providing vitamin D
analogs in patients with CKD often poses a dilemma because
studies have linked vitamin D treatment to subsequent
vascular calcification.65,66 Of particular importance, 50% of
mortalities in patients with CKD undergoing dialysis treat-
ment were shown to be related to vascular calcification.38,66
Vitamin D-independent vascular calcification was shown
recently in genetically altered mouse models. For instance,
klotho-knockout mice have increased renal expression of
sodium/phosphate co-transporters (NaPi2a), associated with
severe hyperphosphatemia (Figure 2).20,53–55,67 Such serum
biochemical changes in klotho-knockout mice led to extensive
soft tissue anomalies and vascular calcification. Interestingly,
lowering the serum phosphate levels in klotho-knockout mice
reduced vascular calcification, despite the presence of
significantly higher serum calcium and 1,25-dihydroxyvita-
min D levels.20,54 This study provides in vivo evidence of
beneficial effects of reducing serum phosphate levels on
preventing vascular calcification, even in the presence of
extremely high serum 1,25-dihydroxyvitamin D levels
(Figure 3).20,54 Such in vivo information may be of particular
importance in designing the therapeutic strategies for
patients with CKD, in whom low serum levels of vitamin D
and phosphate toxicity have been shown to be associated
with high mortality. Phosphate retention in patients with
CKD and dialysis-associated inflammatory responses can
accelerate VSMC apoptosis, as well as induce vascular
calcification and calcifying uremic arteriolopathy or calci-
phylaxis. In the experimental animals, inflammation has
shown to promote vascular calcification, as overexpression of
tumor necrosis factor-a in the vessels resulted in calcification,
possibly by activating wingless-type MMTV integration site
family member activities in the VSMCs.27,39 Recently, other
signaling pathways are also implicated in vascular calcifica-
tion process. For instance, phosphatidylinositol 3-kinase/Akt
signaling pathway has shown to be involved in VSMC
calcification, induced by inflammatory mediators, such as
interferon-g and tumor necrosis factor-a. Suppression of
phosphatidylinositol 3-kinase pathway with wortmannin
(inhibitor of phosphatidylinositol 3-kinase) can increase
inflammatory mediator-induced VSMC calcification, along
with the expression of alkaline phosphatase.68 In patients
with CKD, an inverse association is reported between serum
levels of proinflammatory cytokines (tumor necrosis factor-
a, interleukin-1b, interleukin-6) and Fetuin-A (an inhibitor
of extraskeletal calcification).69 Fetuin-A can inhibit de novo
precipitation of calcium–phosphate, without exerting effects
on already formed hydroxyapatite.70 Of relevance, Fetuin-A-
knockout mice develop severe ectopic calcifications in the
heart, lung, kidney and skin.71
Furthermore, hyperphosphatemia and hypercalcemia
can induce cardiovascular calcification, affecting the
myocardium, and cardiac valves.72 Hyperphosphatemia
(46.5 mg/dl) and elevated Ca P product (472) are known
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Figure 2 | Serum phosphate, calcium, and 1,25 dehydroxyvitamin D levels. Phosphate and calcium levels in wild-type (WT), klotho/,
and NaPi2a//klotho/ double knockout (DKO) mice. Serum phosphate, calcium, and 1,25 dehydroxyvitamin D levels were higher in
klotho–/– mice compared with WT mice at 9 weeks of age. In contrast to klotho–/– mice, serum phosphate levels were markedly reduced in
DKO mice. Note that in contrast to the serum phosphate levels, serum calcium and 1,25 dehydroxyvitamin D levels remained higher in DKO
mice (*Po0.01, versus WT; **Po0.005, versus WT; zPo0.001, versus klotho/; #Po0.05, versus DKO). 1,25 dehydroxyvitamin D3,
1,25(OH)2D3.
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to be related to cardiovascular anomalies associated with
increased mortality in patients with CKD undergoing
hemodialysis treatment.73 Comparable results were also noted
in the experimental model of CKD, in which controlling serum
phosphate levels prevented the development of vascular
calcification.74 Similarly, the administration of calcium
carbonate delayed the progression of aortic calcification in
CKD-induced apolipoprotein-E-knockout mice, possibly
by reducing serum phosphate levels.75 Of relevance, high
serum levels of phosphate and low serum vitamin D levels have
been identified as independent risk factors not only for rapid
deterioration in renal function but also for high mortality
of the pre-dialysis phase in CKD patients.62,63,76
CONCLUSIONS
Vascular calcification is a complex, ectopic biomineralization
process, involving autocrine, paracrine and endocrine inter-
actions of numerous factors (Table 1). There is increasing
evidence suggesting that phosphate toxicity plays an
important role in vascular calcification. Phosphate toxicity
can not only facilitate essential hydroxyapatite deposition in
the calcifying vessels but also initiate the early events by
inflicting apoptotic cell death on both endothelial cells and
VSMCs (Figure 4). Moreover, reducing or eliminating
vascular calcification in klotho-knockout mice—by lowering
serum phosphate levels—provides compelling genetic evi-
dence of vitamin-D-independent calcification, even in the
presence of extremely high serum calcium and 1,25-
dihydroxyvitamin D levels.20,54,77 More importantly, these
results suggest that reducing ‘phosphate toxicity’ should be a
critical therapeutic priority for minimizing the risk of
vascular calcification and disease progression,78 Although
there is no disagreement about the harmful effects of
phosphate toxicity on the survival of CKD patients, the
survival advantage for hemodialysis patients taking vitamin
D was questioned in the recently published Dialysis Out-
comes and Practice Patterns Study.79 Analyzed data from
38,066 Dialysis Outcomes and Practice Patterns Study
participants from 12 countries between 1996 and 2007 did
not show any differences in mortality in patients with or
without vitamin D treatment in the adjusted baseline
standard regression models.79
Delineating the kidney-vascular axis in the context of
regulating calcium, phosphate and vitamin D metabolism in
health and disease will help us not only to determine the
molecular mechanisms of vascular calcification but also in
achieving therapeutic modulation of the involved pathways
and prevent/delay this deadly vascular disorder.
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